T-group (topology)
1075.4.1 Type I ABC exporter transmembrane domain fold
Ligands and drugs
2,562
Member domains
775
with ligand contacts (≤ 4 Å)
30.2% of members
442
with DrugDomain annotations
17.3% of members
318
with a DrugBank compound
12.4% of members
Aggregated over all current member domains of this group. Drug annotations come from DrugDomain; buffers and crystallization additives are excluded from the tables below.
Chemical profile
Chemical profiles are computed for X-groups. 1075.4.1 belongs to X-group 1075 Type II ABC exporter transmembrane domain fold, which binds 8.7 ligand superclasses per 20 proteins, broader than 72% of the 256 X-groups with enough proteins to compare. View its chemical profile →
DrugBank compounds
| DrugBank | PDB ligand | Name | Domains |
|---|---|---|---|
| DB00171 | ATP | ATP | 119 |
| DB16833 | ADP | Adenosine disphosphate | 65 |
| DB02930 | AGS | Adenosine 5'-[gamma-thio]triphosphate | 34 |
| DB01016 | GBM | Glyburide | 30 |
| DB04540 | CLR | Cholesterol | 27 |
| DB00912 | BJX | Repaglinide | 11 |
| DB00143 | GSH | Glutathione | 7 |
| DB08820 | VX7 | Ivacaftor | 6 |
| DB15444 | WJX | Elexacaftor | 6 |
| DB02767 | FTT | (R)-3-hydroxytetradecanoic acid | 4 |
| DB03017 | DAO | Lauric acid | 4 |
| DB03310 | GDS | Glutathione disulfide | 4 |
| DB04372 | DLP | L-Dilinoleoyllecithin | 4 |
| DB06191 | ZQU | Zosuquidar | 4 |
| DB08231 | MYR | Myristic acid | 4 |
| DB00145 | GLY | Glycine | 3 |
| DB01252 | 9I0 | Mitiglinide | 3 |
| DB03429 | CDL | Tetrastearoyl cardiolipin | 3 |
| DB09280 | VX8 | Lumacaftor | 3 |
| DB00141 | NAG | N-Acetylglucosamine | 2 |
Most frequently bound compounds
| PDB ligand | Name | Domains in contact |
|---|---|---|
| ATP | ADENOSINE-5'-TRIPHOSPHATE | 197 |
| ADP | ADENOSINE-5'-DIPHOSPHATE | 82 |
| CLR | CHOLESTEROL | 59 |
| GBM | 5-chloro-N-(2-{4-[(cyclohexylcarbamoyl)sulfamoyl]phenyl}ethyl)-2-methoxybenzamide | 54 |
| Y01 | CHOLESTEROL HEMISUCCINATE | 42 |
| POV | (2S)-3-(hexadecanoyloxy)-2-[(9Z)-octadec-9-enoyloxy]propyl 2-(trimethylammonio)ethyl phosphate | 41 |
| ANP | PHOSPHOAMINOPHOSPHONIC ACID-ADENYLATE ESTER | 37 |
| AGS | PHOSPHOTHIOPHOSPHORIC ACID-ADENYLATE ESTER | 32 |
| BJX | Repaglinide | 30 |
| PTY | PHOSPHATIDYLETHANOLAMINE | 24 |
| P5S | O-[(R)-{[(2R)-2,3-bis(octadecanoyloxy)propyl]oxy}(hydroxy)phosphoryl]-L-serine | 17 |
| E2H | 6-chloranyl-~{N}-(1-methylcyclopropyl)-1,1-bis(oxidanylidene)-4~{H}-thieno[3,2-e][1,2,4]thiadiazin-3-amine | 16 |
| HGmetal | MERCURY (II) ION | 16 |
| MGmetal | MAGNESIUM ION | 16 |
| 4C8 | 2,4-dibromophenyl 2,4,6-tribromophenyl ether | 14 |
| HT1 | 2'-(4-ETHOXYPHENYL)-5-(4-METHYL-1-PIPERAZINYL)-2,5'-BI-BENZIMIDAZOLE | 14 |
| JIZ | (4~{S},11~{S},18~{S})-4,11-dimethyl-18-(sulfanylmethyl)-6,13,20-trithia-3,10,17,22,23,24-hexazatetracyclo[17.2.1.1^{5,8}.1^{12,15}]tetracosa-1(21),5(24),7,12(23),14,19(22)-hexaene-2,9,16-trione | 14 |
| JSG | (2~{R},4~{R},5~{R},6~{R})-6-[(1~{R})-1,2-bis(oxidanyl)ethyl]-2-[(2~{R},4~{R},5~{R},6~{R})-6-[(1~{R})-1,2-bis(oxidanyl)ethyl]-5-[(2~{S},3~{S},4~{R},5~{R},6~{R})-6-[(1~{S})-1,2-bis(oxidanyl)ethyl]-4-[(2~{R},3~{S},4~{R},5~{S},6~{R})-6-[(1~{S})-2-[(2~{S},3~{S},4~{S},5~{S},6~{R})-6-[(1~{S})-1,2-bis(oxidanyl)ethyl]-3,4,5-tris(oxidanyl)oxan-2-yl]oxy-1-oxidanyl-ethyl]-3,4-bis(oxidanyl)-5-phosphonooxy-oxan-2-yl]oxy-3-oxidanyl-5-phosphonooxy-oxan-2-yl]oxy-2-carboxy-2-[[(2~{R},3~{S},4~{R},5~{R},6~{R})-5-[[(3~{R})-3-dodecanoyloxytetradecanoyl]amino]-6-[[(2~{R},3~{S},4~{R},5~{R},6~{R})-3-oxidanyl-5-[[(3~{R})-3-oxidanyltetradecanoyl]amino]-4-[(3~{R})-3-oxidanyltetradecanoyl]oxy-6-phosphonooxy-oxan-2-yl]methoxy]-3-phosphonooxy-4-[(3~{R})-3-tetradecanoyloxytetradecanoyl]oxy-oxan-2-yl]methoxy]oxan-4-yl]oxy-4,5-bis(oxidanyl)oxane-2-carboxylic acid | 14 |
| 3PE | 1,2-Distearoyl-sn-glycerophosphoethanolamine | 13 |
| HEB | HEME B/C | 12 |